Mozhno li dostignut' effektivnogo glikemicheskogo kontrolya sakharnogo diabeta 2 tipa: preimushchestva rannego naznacheniya insulina
https://doi.org/10.14341/2072-0351-5949
Abstract
Приоритеты при выборе фармакотерапии СД 2 в настоящее время достаточно обоснованно и точно определены в достигнутом консенсусе ADA и EASD. Прогрессирующее ухудшение метаболического статуса и толерантность к улучшению функции ?-клеток обосновывает более агрессивную тактику лечения СД 2, оправданную уже на начальных стадиях заболевания. Ранняя инсулинотерапия в индивидуально подобранных дозах с использованием современных аналогов человеческого инсулина (Лантус) в виде комбинации с ПСП или монотерапия инсулином ? это лучший путь достижения основных целей лечения, открывающий широкие перспективы: поддержание долгосрочного метаболического контроля и предотвращения или отсрочки сосудистых осложнений.
About the Author
Elena Valer'evna Biryukova
Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
References
1. Федеральная целевая программа «Сахарный диабет»: Методические рекомендации - Москва, 2002
2. Adeghate E., Schatiner P., Dunn E. An update on the etiology and epidemiology of diabetes mellitus. // Ann. N.Y. Acad. Sci. 2006; 1084(1): 1-29.
3. Barnett A: A review of basal insulins. // Diabet Med 2003;20:873-885
4. Fritsche A., Schweitzer M.A., H ring H.U. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial.// Ann Intern Med. 2003;138(12):952-9.
5. Giorgino F., Laviola L., Leonardini A. Pathoysiolody of type 2 diabetes: rationale for different oral antidiabetic treatment strategies. // Diabetes research and Clinical practice 2005; 68(1), S22-9
6. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004;27:17-20.
7. Kuusisto J., Mykkanen J., Pyorala K., Laakso M. Non- insulin dependent diabetes and its metabolic control are important predictors of stroke in elderly subjects. // Stroke. - 1994; 25(6): 1157-1164 13
8. McKeage K., Goa K.L. Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus. //Drugs. 2001;61(11):1599-624.
9. McFarlane S.I., Banerij M., Sowers J.R. Insulin resistance and cardiovascular disease. // J Clin Endocrinol Metab. 2001; 86: 713-8
10. Nathan D.M., Buse J.B., Davidson M.B. et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. // Diabetes Care 2006;29:1963-1972
11. Nathan D.M. Initial management of glycemia in type 2 Diabetes Mellitus // Clinical Practice. 2002; 347(17): 1342-49.
12. Riddle M., Rosenstock J., Gerich J. Investigators IGS: The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetes patients.// Diabetes Care 2003;26:3080-3086
13. Ruigomez A., Rodrigues L.A. Presence of diabetes related complication at the time of NIDDM diagnosis: an important prognostic factor // Eur. J. Epidemiol. 1998; 14(15): 439 -445.
14. Schreiber S.A., Haak T. Insulin glargine benefits patients with type 2 diabetes inadequately controlled on oral antidiabetic treatment: an observational study of everyday practice in 12,216 patients.// Diabetes Obes Metab. 2007; 9(1):31-8.
15. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Golden SH: Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. // Ann Intern Med 2004, 141:421-431.
16. Shim W. S., Kim S. K., Kim H. J. Decrement of postprandial insulin secretion determines the progressive nature of type-2 diabetes. // Eur. J. Endocrinol. 2006; 155(4): 615 - 622.
17. Ubink-Veltman L.J., Bilo H.J., Groenier K.H. et al. Prevalens, incidence and mortality of type 2 diabetes mellitus revisited: a prospective populacion- based study in the Netterlands (ZODIAC-1).// Eur JEpidemiol. 2003;18(8):793-800.
18. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. // Lancet 1998; 352:837-53.
19. Yki-Jarvinen H., Dressler A., Ziemen M.. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. // Diabetes Care2000; 23:1130-6
20. Yki-Jarvinen H., Kauppinen-M kelin R., Tiikkainen M., V h talo M. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. // Diabetologia. 2006;49(3):442-51.
21. Younis N., Soran H., Bowen-Jones D. Insulin glargine: a new basal insulin analogue. // Q J Med 2002; 95: 757-761
22. Yki-Jarvinen H: Insulin therapy in type 2 diabetes: role of the long-acting insulin glargine analogue. // Eur J Clin Invest 2004; 34:410-416
23. Wang F., Carabino J.M., Vergara C.M. Insulin glargine: a systematic review of a long-acting insulin analogue.// Clin Ther. 2003;25(6):1541-77
24. Wild S., Roglic A., Green R. et al. Global prevalence of diabetes: estimates for year 2000 and projections for 2030. // Diabetes Care 2004; 27(5): 1047 - 53.
Review
For citations:
Biryukova E.V. Mozhno li dostignut' effektivnogo glikemicheskogo kontrolya sakharnogo diabeta 2 tipa: preimushchestva rannego naznacheniya insulina. Diabetes mellitus. 2008;11(1):67-72. (In Russ.) https://doi.org/10.14341/2072-0351-5949
Views:
1266
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
